A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Trial to Evaluate Pharmacokinetics, Pharmacodynamics, and Safety of AT-752 in Patients With Dengue Infection
Latest Information Update: 07 Mar 2024
Price :
$35 *
At a glance
- Drugs AT 752 (Primary)
- Indications Dengue
- Focus Proof of concept; Therapeutic Use
- Acronyms DEFEND-2
- Sponsors Atea Pharmaceuticals
- 17 Mar 2023 The Interventional Study Model was modified in the protocol, and the trial will now employ Sequential Assignment rather than Parallel Assignment and reduce the number of arms from 4 to 3, the protocol was amended.
- 17 Mar 2023 Status changed from recruiting to discontinued.
- 28 Feb 2023 Results presented in an Atea pharmaceuticals media release.